Roivant Sciences (ROIV) News Today $10.67 -0.16 (-1.48%) Closing price 03/25/2025 04:00 PM EasternExtended Trading$10.70 +0.03 (+0.27%) As of 03/25/2025 07:26 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 Time Period Roivant Sciences Ltd. (NASDAQ:ROIV) COO Sells $3,489,673.32 in StockRoivant Sciences Ltd. (NASDAQ:ROIV - Get Free Report) COO Eric Venker sold 315,522 shares of the firm's stock in a transaction dated Thursday, March 20th. The stock was sold at an average price of $11.06, for a total value of $3,489,673.32. Following the sale, the chief operating officer now directly owns 959,457 shares of the company's stock, valued at $10,611,594.42. The trade was a 24.75 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link.March 25 at 10:30 PM | marketbeat.comRoivant Sciences Ltd. (NASDAQ:ROIV) COO Eric Venker Sells 434,478 SharesRoivant Sciences Ltd. (NASDAQ:ROIV - Get Free Report) COO Eric Venker sold 434,478 shares of the company's stock in a transaction on Monday, March 24th. The stock was sold at an average price of $10.82, for a total value of $4,701,051.96. Following the sale, the chief operating officer now owns 1,127,290 shares of the company's stock, valued at $12,197,277.80. This trade represents a 27.82 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this hyperlink.March 25 at 10:30 PM | marketbeat.comIs Roivant Sciences Ltd. (NASDAQ:ROIV) One of The Best Stocks to Buy According to Billionaire David Einhorn?March 25 at 2:45 PM | insidermonkey.comInsider Selling: Roivant Sciences Ltd. (NASDAQ:ROIV) COO Sells 315,522 Shares of StockMarch 25 at 4:04 AM | insidertrades.comRoivant Sciences finalizes consulting agreement with former officerMarch 22, 2025 | investing.comRoivant Sciences Ltd. (NASDAQ:ROIV) Holdings Lessened by Corbin Capital Partners L.P.Corbin Capital Partners L.P. reduced its holdings in shares of Roivant Sciences Ltd. (NASDAQ:ROIV - Free Report) by 69.1% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 46,641 shares of the company's stock afMarch 22, 2025 | marketbeat.comRoivant Sciences finalise un accord de conseil avec une ancienne dirigeanteMarch 21, 2025 | fr.investing.comRoivant Sciences (NASDAQ:ROIV) Trading Up 5% - Here's WhyRoivant Sciences (NASDAQ:ROIV) Trading 5% Higher - Time to Buy?March 20, 2025 | marketbeat.comPrivium Fund Management B.V. Cuts Position in Roivant Sciences Ltd. (NASDAQ:ROIV)Privium Fund Management B.V. reduced its stake in shares of Roivant Sciences Ltd. (NASDAQ:ROIV - Free Report) by 55.5% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 215,506 shares of the company's stock after sellingMarch 20, 2025 | marketbeat.comRoivant And Immunovant Won't Seek Approval Despite Phase 3 Win. Why Shares Rose.March 19, 2025 | msn.comRoivant And Immunovant Won't Seek Approval Despite Phase 3 Win. Why Shares Rallied.March 19, 2025 | msn.comRoivant, Immunovant Succeed In Phase 3. But There's A Twist — And Shares Tumbled.March 19, 2025 | investors.comRoivant Announces Positive Results for Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) StudiesMarch 19, 2025 | globenewswire.comTejara Capital Ltd Cuts Stock Position in Roivant Sciences Ltd. (NASDAQ:ROIV)Tejara Capital Ltd decreased its position in Roivant Sciences Ltd. (NASDAQ:ROIV - Free Report) by 42.7% during the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 813,550 shares of the company's stock after selling 607,440 shares during the period. Roivant SciencesMarch 19, 2025 | marketbeat.comRoivant Sciences Ltd. (NASDAQ:ROIV) Receives Consensus Rating of "Buy" from AnalystsShares of Roivant Sciences Ltd. (NASDAQ:ROIV - Get Free Report) have been assigned a consensus recommendation of "Buy" from the seven analysts that are currently covering the stock, Marketbeat Ratings reports. One equities research analyst has rated the stock with a hold rating, five have given aMarch 19, 2025 | marketbeat.comReviewing Roivant Sciences (NASDAQ:ROIV) & Orgenesis (NASDAQ:ORGS)March 19, 2025 | americanbankingnews.comRoivant to Host Investor Webcast at 8:00 AM ET on Wednesday, March 19 to Review Results from Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) ProgramsMarch 18, 2025 | globenewswire.comSkandinaviska Enskilda Banken AB publ Reduces Stake in Roivant Sciences Ltd. (NASDAQ:ROIV)Skandinaviska Enskilda Banken AB publ lessened its stake in shares of Roivant Sciences Ltd. (NASDAQ:ROIV - Free Report) by 42.1% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 115,476 shares of the company's sMarch 18, 2025 | marketbeat.comAmundi Raises Stock Position in Roivant Sciences Ltd. (NASDAQ:ROIV)Amundi raised its stake in shares of Roivant Sciences Ltd. (NASDAQ:ROIV - Free Report) by 15.0% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 337,515 shares of the company's stock after purchasing an addMarch 17, 2025 | marketbeat.comCharles Schwab Investment Management Inc. Grows Holdings in Roivant Sciences Ltd. (NASDAQ:ROIV)Charles Schwab Investment Management Inc. raised its position in shares of Roivant Sciences Ltd. (NASDAQ:ROIV - Free Report) by 1.6% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 2,812,502 sharesMarch 17, 2025 | marketbeat.comMonimus Capital Management LP Purchases Shares of 137,058 Roivant Sciences Ltd. (NASDAQ:ROIV)Monimus Capital Management LP purchased a new stake in Roivant Sciences Ltd. (NASDAQ:ROIV - Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund purchased 137,058 shares of the company's stock, valued at approximately $1,621,000. Roivant SciMarch 16, 2025 | marketbeat.comMonaco Asset Management SAM Acquires 35,000 Shares of Roivant Sciences Ltd. (NASDAQ:ROIV)Monaco Asset Management SAM grew its holdings in Roivant Sciences Ltd. (NASDAQ:ROIV - Free Report) by 35.0% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 135,000 shares of the company's stock after purchaMarch 15, 2025 | marketbeat.comThompson Siegel & Walmsley LLC Increases Position in Roivant Sciences Ltd. (NASDAQ:ROIV)Thompson Siegel & Walmsley LLC increased its stake in shares of Roivant Sciences Ltd. (NASDAQ:ROIV - Free Report) by 10.1% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 565,337 shares of the company's stockMarch 15, 2025 | marketbeat.comRoivant at Leerink’s Conference: Strategic Insights and DevelopmentsMarch 12, 2025 | investing.comDoes Roivant (ROIV) Offer an Attractive Risk Reward Opportunity?March 7, 2025 | msn.comBank of New York Mellon Corp Boosts Holdings in Roivant Sciences Ltd. (NASDAQ:ROIV)Bank of New York Mellon Corp boosted its position in shares of Roivant Sciences Ltd. (NASDAQ:ROIV - Free Report) by 17.4% during the 4th quarter, according to its most recent 13F filing with the SEC. The fund owned 3,439,540 shares of the company's stock after purchasing an additional 510,398 shareMarch 7, 2025 | marketbeat.comRoivant Sciences (NASDAQ:ROIV) Upgraded at Cantor FitzgeraldCantor Fitzgerald upgraded Roivant Sciences to a "strong-buy" rating in a research note on Tuesday.March 6, 2025 | marketbeat.com10 Cash-Rich Mid Cap Stocks To Buy NowMarch 5, 2025 | insidermonkey.comNew York Life Investment Management LLC Invests $454,000 in Roivant Sciences Ltd. (NASDAQ:ROIV)New York Life Investment Management LLC acquired a new position in shares of Roivant Sciences Ltd. (NASDAQ:ROIV - Free Report) in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 38,383 shares of the companyMarch 5, 2025 | marketbeat.comRoivant Sciences Ltd. (ROIV): Among the Cash-Rich Mid Cap Stocks to Buy NowMarch 3, 2025 | insidermonkey.comGenevant Sciences and Arbutus Biopharma Initiate International Patent Infringement Enforcement Actions Against ModernaMarch 3, 2025 | globenewswire.comRoivant Sciences Ltd. (NASDAQ:ROIV) Shares Bought by New York State Common Retirement FundNew York State Common Retirement Fund boosted its stake in shares of Roivant Sciences Ltd. (NASDAQ:ROIV - Free Report) by 15.2% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 219,793 shares of the company's stock after acquMarch 2, 2025 | marketbeat.comPrincipal Financial Group Inc. Has $11.65 Million Stake in Roivant Sciences Ltd. (NASDAQ:ROIV)Principal Financial Group Inc. lessened its holdings in Roivant Sciences Ltd. (NASDAQ:ROIV - Free Report) by 2.5% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 984,519 shares of the company's stock after selling 25,239February 28, 2025 | marketbeat.comHandelsbanken Fonder AB Has $1.34 Million Stock Position in Roivant Sciences Ltd. (NASDAQ:ROIV)Handelsbanken Fonder AB lowered its stake in Roivant Sciences Ltd. (NASDAQ:ROIV - Free Report) by 40.9% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 113,109 shares of the company's stock after selliFebruary 27, 2025 | marketbeat.comHow rich is Vivek Ramaswamy?February 26, 2025 | msn.comNet worth of Vivek Ramaswamy: Roviant Sciences founder who is running for Ohio governorFebruary 26, 2025 | msn.comInsider Selling: Roivant Sciences Ltd. (NASDAQ:ROIV) COO Sells 100,000 Shares of StockFebruary 26, 2025 | insidertrades.comEarly Warning Report Issued Pursuant to National Instrument 62‐103: Roivant announces Resignation and Replacement of Arbutus BoardFebruary 25, 2025 | finance.yahoo.comRoivant Sciences announces replacement of Arbutus Biopharma boardFebruary 25, 2025 | markets.businessinsider.comRoivant Sciences Ltd. (NASDAQ:ROIV) COO Sells $1,065,000.00 in StockRoivant Sciences Ltd. (NASDAQ:ROIV - Get Free Report) COO Eric Venker sold 100,000 shares of the stock in a transaction dated Thursday, February 20th. The stock was sold at an average price of $10.65, for a total transaction of $1,065,000.00. Following the sale, the chief operating officer now owns 896,869 shares of the company's stock, valued at $9,551,654.85. This trade represents a 10.03 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.February 25, 2025 | marketbeat.comHow Vivek Ramaswamy got rich before going into politicsFebruary 23, 2025 | usatoday.comRoivant Sciences Ltd. (NASDAQ:ROIV) Given Consensus Rating of "Buy" by AnalystsRoivant Sciences Ltd. (NASDAQ:ROIV - Get Free Report) has received a consensus rating of "Buy" from the seven ratings firms that are covering the stock, Marketbeat.com reports. One equities research analyst has rated the stock with a hold rating, five have issued a buy rating and one has given aFebruary 22, 2025 | marketbeat.comInsider Selling: Roivant Sciences Ltd. (NASDAQ:ROIV) CAO Sells 227,500 Shares of StockRoivant Sciences Ltd. (NASDAQ:ROIV - Get Free Report) CAO Rakhi Kumar sold 227,500 shares of Roivant Sciences stock in a transaction dated Thursday, February 13th. The stock was sold at an average price of $10.43, for a total value of $2,372,825.00. Following the completion of the transaction, the chief accounting officer now owns 163,264 shares of the company's stock, valued at approximately $1,702,843.52. This represents a 58.22 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink.February 19, 2025 | marketbeat.comRakhi Kumar Sells 227,500 Shares of Roivant Sciences Ltd. (NASDAQ:ROIV) StockFebruary 19, 2025 | insidertrades.comEric Venker Sells 218,041 Shares of Roivant Sciences Ltd. (NASDAQ:ROIV) StockRoivant Sciences Ltd. (NASDAQ:ROIV - Get Free Report) COO Eric Venker sold 218,041 shares of the stock in a transaction that occurred on Thursday, February 13th. The shares were sold at an average price of $10.42, for a total transaction of $2,271,987.22. Following the sale, the chief operating officer now directly owns 896,869 shares of the company's stock, valued at $9,345,374.98. This represents a 19.56 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website.February 15, 2025 | marketbeat.comInsider Selling: Roivant Sciences Ltd. (NASDAQ:ROIV) COO Sells 218,041 Shares of StockFebruary 15, 2025 | insidertrades.comHC Wainwright Reiterates Buy Rating for Roivant Sciences (NASDAQ:ROIV)HC Wainwright reiterated a "buy" rating and issued a $18.00 target price on shares of Roivant Sciences in a research note on Tuesday.February 11, 2025 | marketbeat.comRoivant Sciences Ltd. (NASDAQ:ROIV) Q3 2024 Earnings Call TranscriptFebruary 11, 2025 | msn.comRoivant Sciences (ROIV) Receives a Hold from Bank of America SecuritiesFebruary 11, 2025 | markets.businessinsider.comRoivant Sciences price target lowered to $12 from $13 at BofAFebruary 11, 2025 | markets.businessinsider.com Remove Ads Get Roivant Sciences News Delivered to You Automatically Sign up to receive the latest news and ratings for ROIV and its competitors with MarketBeat's FREE daily newsletter. Email Address ROIV Media Mentions By Week ROIV Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ROIV News Sentiment▼0.660.71▲Average Medical News Sentiment ROIV News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ROIV Articles This Week▼175▲ROIV Articles Average Week Remove Ads Get Roivant Sciences News Delivered to You Automatically Sign up to receive the latest news and ratings for ROIV and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies ONC News Today BNTX News Today TEVA News Today SMMT News Today ITCI News Today GMAB News Today MRNA News Today VTRS News Today RDY News Today ASND News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ROIV) was last updated on 3/26/2025 by MarketBeat.com Staff From Our PartnersDOGE could send 6 AI stocks through the roofStay alert for Elon Musk and the Department of Government Efficiency's next move … Expect an announcement f...Weiss Ratings | SponsoredThe Dirty Secret About Gold Mining Stocks...Here's something most gold analysts won't tell you: 90% of gold mining companies actually destroy sharehold...Golden Portfolio | SponsoredEx CIA predicts 40% “double crash” – April 11The scientists here don’t study deadly viruses… directed energy weapons… or even weather control technology… ...Paradigm Press | SponsoredDOGE officially begins retirement transformationElon Musk's Department of Government Efficiency ("DOGE") just announced the first-ever "fully digital retireme...Altimetry | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | SponsoredNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredGold Hits $3,000… Here’s How You Can Get More for Under $20With gold surging to record highs, currently trading above $3,000 an ounce, and central banks aggressively sto...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Roivant Sciences Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Roivant Sciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
